IP Library Granted Patent US 9,480,775
Granted Patent B2
US 9,480,775 · App. 14/665,820 · Granted Nov 1, 2016

Polysaccharide and protein-polysaccharide cross-linked hydrogels for soft tissue augmentation

Inventors: Karina Heredia Guillen (Santa Barbara, CA); Ahmet Tezel (Fort Worth, TX)
Assignee: Allergan, Inc.
A61L27/26A61K47/36A61K47/42A61L27/20A61L27/52A61L27/54A61L2300/402A61L2300/404A61L2300/41A61L2300/426A61L2300/43A61L2300/434A61L2300/442
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,480,775
App. No.
14/665,820
Granted
Nov 1, 2016
Kind
B2
Abstract

Disclosed herein are cohesive soft tissue fillers, for example, dermal and subdermal fillers, based on hyaluronic acids and optionally including proteins. In one aspect, hyaluronic acid-based compositions described herein include zero-length cross-linked moieties and optionally at least one active agent. The present hyaluronic acid-based compositions have enhanced flow characteristics, hardness, and persistence compared to known hyaluronic acid-based compositions. Methods and processes of preparing such hyaluronic acid-based compositions are also provided.

Claims (20)

1. A hydrogel composition for soft tissue augmentation, comprising:

a hyaluronic acid polymer crosslinked with collagen via a zero-length crosslinking agent;

wherein said hydrogel is formed by:

(a) reacting said hyaluronic acid polymer with said collagen via said zero-length cross-linking agent;

wherein said zero-length cross-linking agent is a carbodiimide;

thereby providing a crosslinked hyaluronic acid/collagen-based composition; and

(b) sterilizing the crosslinked hyaluronic acid/collagen-based composition using a gaseous agent or an irradiation source, wherein the irradiation source comprises ultraviolet light, visible light or microwaves.

2. The hydrogel composition of claim 1 , wherein said zero-length cross-linking agent is 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC).

3. The hydrogel composition according to claim 1 , wherein said zero-length cross-linking agent is reacted with said hyaluronic acid polymer and said collagen at neutral pH, wherein said neutral pH is between about 6.0 and about 8.0.

4. The hydrogel composition according to claim 3 , wherein said neutral pH is between about 6.5 and about 7.5.

5. The hydrogel composition according to claim 4 , wherein said neutral pH is about 7.0.

6. The hydrogel composition according to claim 1 , further comprising an active agent selected from the group consisting of an enzyme inhibitor, anesthetic agent, medicinal neurotoxin, antioxidant, anti-infective agent, anti-inflammatory agent, ultraviolet light blocking agent, dye, hormone, immunosuppressant, and combinations thereof.

7. The hydrogel composition according to claim 6 , wherein the active agent is an anesthetic agent.

8. The hydrogel composition according to claim 1 , wherein the hydrogel is sterilized using the gaseous agent.

9. The hydrogel composition according to claim 1 , wherein the hydrogel is sterilized using the irradiation source.

10. The hydrogel of claim 1 , having a hyaluronic acid concentration of about 15 mg/mL to about 80 mg/mL.

11. The hydrogel of claim 1 , having a hyaluronic acid concentration of about 15 mg/mL to about 30 mg/mL.

12. The hydrogel of claim 1 , having a hyaluronic acid concentration of about 26 mg/mL.

13. Previously presented) The hydrogel of claim 2 , wherein said zero-length cross-linking agent is reacted with said hyaluronic acid polymer and said collagen in the presence of N-hydroxysuccinimide (NHS).

14. The hydrogel composition according to claim 7 , wherein the anesthetic agent is lidocaine.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 14, 2015
From: GUILLEN, KARINA HEREDIA; TEZEL, AHMET
To: ALLERGAN, INC.
Reel/Frame 036331/0432 →
Continuity (4)
Continuation 14219652 · Mar 19, 2014
Division 13052690 · Mar 21, 2011
Provisional Application 61316283 · Mar 22, 2010
Related Publication 20150196684A1 · Jul 16, 2015